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Abstract   Hypertensive disorders of pregnancy (HDP) are normally treated to 
avoid maternal complications. In this study we aimed to investigate if there was an 
effect of maternal HDP treatment on the cerebral autoregulation of the neonates by 
analyzing measurements of mean arterial blood pressure (MABP) and rScO2 by 
means of correlation, coherence and transfer function analysis. We found that 
these infants presented higher values of transfer function gain, which indicates 
impaired cerebral autoregulation, with a decreasing trend towards normality. We 
hypothesized that this trend was due to a vasodilation effect of the maternal use of 
labetalol due to accumulation, which disappeared by the third day after birth. 
Therefore, we investigated the values of pulse pressure in order to find evidence 
for a vasodilatory effect. We found that lower values of pulse pressure were 
present in these infants when compared with a control population; which, together 
with increased transfer function gain values, suggests an effect of the drug on the 
cerebral autoregulation. 
1 Introduction 
Hypertension is the most common medical disorder encountered during pregnancy 
and is estimated to occur in about 6-8% of pregnancies [1]. Hypertensive disorders 
of pregnancy (HDP) should be treated in order to prevent maternal complications 
and improve fetal maturity by permitting prolongation of pregnancy and 
minimizing fetal exposure to possible adverse effects of antihypertensive 
treatment. There are several advantages and disadvantages of HDP treatment [1]. 
In pregnancy longer than 34 weeks, induction of labour in the occurrence of 
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hypertension and pre-eclampsia is generally considered the best treatment to 
improve maternal and neonatal outcome. However, there is considerable 
morbidity in late preterms explained by the mode of delivery and gestational age 
[2]. Labetalol is a selective α-1 (peripheral vasodilation) and non-selective β 
receptoragonist (preventing reflex tachycardia and maintaining cardiac output), 
which is often used in HDP treatment. Due to its lipophilic properties it easily 
passes the placental barrier, which is in essence a lipid membrane. Hypotension, 
bradycardia and hypoglycaemia are possible neonatal side effects, but may also 
occur in (preterm) infants regardless of labetalol exposure. Labetalol’s half-life in 
adults is approximately 6 hours but accumulation occurs. However, half-life after 
maternal use in a preterm baby with clinical signs of β-blockage was 24 hours [3]. 
Conflicting evidence exists for specific neonatal side effects described after use of 
labetalol for maternal hypertension. Nevertheless oral and intravenous labetalol is 
used as a first or second-line treatment in HDP due to its highly effective 
antihypertensive properties and because it has a better profile than hydralazine and 
other β-blockers [4, 5]. Scarce information on neonatal cerebral haemodynamics 
in gestational hypertension and pre-eclampsia is available. However, not much is 
known about the true influence of maternal use of labetalol on the neonatal 
hemodynamic parameters (bradycardia, hypotension) in the brain, mainly since 
cerebral fetal circulation is subject to changes due to brainsparing in severe pre-
eclampsia. We aimed to investigate labetalol-induced effects on neonatal cerebral 
autoregulation mechanisms during the first three days of life. 
2 Methods 
Data. The study was performed in 56 infants from the Wilhelmina’s Children’s 
Hospital Utrecht (the Netherlands), with a gestational age of 29 (24.7- 31.9) weeks 
and a birth weight of 960 (540-1585) grams. In all infants peripheral oxygen 
saturation (SaO2) was measured continuously by pulse oximetry, mean arterial 
blood pressure (MABP) by an indwelling arterial catheter. With NIRS, regional 
oxygen saturation (rScO2) was continuously and noninvasively recorded using the 
INVOS4100 (Somanetics). MABP, SaO2 and NIRS signals were simultaneously 
measured during the first three days of life. From the 56 infants 16 correspond to 
control subjects, and 40 correspond to the group of mothers who were treated for 
HDP. From the HDP group 21 neonates correspond to mothers treated with 
labetalol (HPD+Lab) and 19 correspond to mothers with other treatment (HPD-
Lab). The subjects from the three groups were matched for gestational age, birth 
weight and gender. 
Signal Analysis.  Artifacts shorter than 30 seconds were removed and corrected by 
interpolation using robust least squares support vector machines for function 
estimation [6]. Artifacts longer than 30 seconds were truncated. Remaining 
artifacts, if any, were removed manually. Hence, a single continuous measurement 
was replaced by a set of continuous artifact-free segments. The resulting signals 
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were filtered with a mean average filter and then downsampled to 1Hz in order to 
obtain a common sampling frequency.  
Mathematical Tools. Cerebral autoregulation was assessed by means of 
correlation, coherence and transfer function analysis between MABP and rScO2. 
The correlation, coherence and transfer function scores were calculated using a 
time-sliding window of length 15 minutes and overlapping time of 1 minute. 
Coherence and transfer function analysis were performed using the Welch method 
for the calculation of the respective cross-power and auto-power spectral densities. 
This method involves a further segmentation of the signals into 5-minute epochs 
with an overlapping of 4.5 minutes. The average of the coefficients in the 
frequency ranges 0.003Hz-0.02Hz (very low frequency range: VLF), 0.02Hz- 
0.05Hz (low frequency range: LF) and 0.05Hz-0.1Hz (high frequency range: HF) 
were calculated [7] for further analysis. The transfer function was calculated with 
the following formula: 
 
 
where  fGio represents the input-output cross-power spectrum and  fGii  
represents the input auto-power spectrum. In addition, the pulse pressure was 
calculated as the difference between the systolic and diastolic blood pressure 
measurements. Figure 1 shows a representative set of measurements for a control 
subject. 
Statistical Analysis. To assess whether the scores and pulse pressure values were 
different between the populations the non-parametric Kruskal-Wallis test was 
used, due to the lack of normality in the data distributions. The statistical analysis 
was performed using the statistics toolbox from MATLAB. All reported p-values 
were two-tailed and a nominal p-value < 0.05 was considered as statistically 
significant. 
3 Results 
When comparing the correlation, coherence and gain values for the three different 
populations, taking the complete measurements for the first three days of life per 
group, no statistically significant differences between the scores were found. 
However, when the analysis was performed in a day-by-day basis, the HDP+Lab 
presented higher values of gain during the first day of life, in the VLF and LF 
bands, when compared with the gain values for the Control and the HDP-Lab 
group (p<0.05). In addition, the gain values during the first day of life, in the VLF 
and LF bands, for the HDP+Lab population were higher than the values in the 
second and third day (p<0.05). This behaviour indicates a progression towards 
normality. Figure 2 shows the gain for a representative subject from the HBP+Lab 
group. Correlation, coherence and phase were still not statistically significant.  
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Pulse pressure values were lower for the HDP+Lab group when compared with 
the other groups. In addition, for the three populations the pulse pressure values 
were lower during the first day of life and presented an increased profile in the 
second and third day. Figure 3 shows the median values of pulse pressure for the 
three different populations and its evolution during the first three days of life. In 
Table 1 the median values of pulse pressure and its range of variation (minimum – 
maximum values) are indicated. 
Table 1. Pulse pressure values for the different populations during the first three days of life (all 
values are given in mmHg). 
 
 Day 1 Day 2 Day 3 
Control 16.08 (5.97-27.54) 21.50 (10.25-28.47) 23.07 (15.73-32.64) 
HDP+Lab 12.94 (9.32-20.17) 16.10 (8.24-25.11) 17.47 (7.67-27.11) 
HDP-Lab 16.76 (9.05-23.18) 17.45 (9.87-27.34) 19.76 (10.04-27.87) 
4 Discussion and Conclusion 
In this study we found that the maternal use of labetalol induces high values of the 
transfer function gain between MABP and rScO2. These high values are 
concomitants with low values of pulse pressure. In [8] low values of pulse 
pressure indicate the presence of vasodilation due to the use of drugs for 
hypertension treatment. However, labetalol is a non-selective β antagonist; its 
action also reduces cardiac contractility which is reflected as a reduction in pulse 
pressure. When comparing pulse pressure values from the HDP+Lab and HDP-
Lab group a stronger reduction is observed in the HDP+Lab group, this may be 
caused by a combination of vasodilation and reduction in cardiac contractility. We 
hypothesized that vasodilation was present in this group due to the concomitant 
reduction in pulse pressure and increase in transfer function gain values. 
Vasodilation reduces the effect of the myogenic mechanism responsible for 
cerebral autoregulation, which increases the transfer function gain. This 
vasodilation may be produced by the accumulation of labetalol due to its maternal 
use [9]. Interestingly, a trend towards normality can be seen in the gain and pulse 
pressure values. The gain values return to normality by the end of the third day, 
while the pulse pressure values were still lower than normal by then. This may be 
due to a decrease in labetalol. This vasodilatory effect might also be caused by 
brainspairing. In [10] higher mean values in cerebral blood flow velocity were 
reported in children with evidence of brainsparing. However, no differences were 
found in the amount of neonates that presented brainsparing between the 
HDP+Lab and HDP-Lab groups. 
Correlation, Coherence and transfer function phase didn’t present differences 
between the studied populations. This may be due to the fact that impaired 
5 
cerebral autoregulation is reflected not only by a coupled dynamics between 
MABP and cerebral blood flow, but also by the strength of this relation. This 
strength is assessed by the gain of the transfer function but not by the correlation 
and coherence scores. Moreover, in a recent study carried out in our group [11], 
we found that, among the aforementioned methods, transfer function analysis is 
the most robust method for cerebral autoregulation assessment. This result is in 
agreement with the results provided by [12]. 
In conclusion, there is evidence indicating that labetalol induces changes in the 
cerebral autoregulation mechanism of the neonates possibly due to its 
accumulation. This accumulation of labetalol might produce vasodilation, which 
leads to high values of gain, impairing the myogenic mechanism of cerebral 
autoregulation. Further studies are necessary to evaluate whether this phenomenon 
also has an effect on the later neurological outcome of the patients. 
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Fig. 1. Measurements of rScO2, MABP and Pulse pressure for one of the subjects during the first 
day of life. 
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Fig. 2. Gain values for a representative subject from the HDP+Lab group. Gain values during the 
first, the second, and third day are shown together with the values from a control subject for 
comparison.  
 
 
 
Fig. 3. Median values of pulse pressure for the three different groups, Control, HDP+Lab and 
HDP-Lab, during the first three days of life. 
